Alnylam: A Loud Silence (B)

Supplement to the (A) Case, HBS No. 824-041. Alnylam had built a platform to develop novel RNA interference (RNAi) therapeutics, but CEO John Maraganore was deep in thought on how to address several challenges. After more than a decade, the company was preparing to become a commercial organization. Was it ready, and how would it approach market decisions? Furthermore, Maraganore wanted the board to agree on implementing Value-Based Agreements for pricing of one new drug, a rarity in the world of big pharma. Maraganore faced numerous challenges as he charted the next phase of Alnylam’s journey.